321 related articles for article (PubMed ID: 21947887)
1. The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease.
Simões E Silva AC; Flynn JT
Pediatr Nephrol; 2012 Oct; 27(10):1835-45. PubMed ID: 21947887
[TBL] [Abstract][Full Text] [Related]
2. Effects of RAAS Inhibitors in Patients with Kidney Disease.
Zhang F; Liu H; Liu D; Liu Y; Li H; Tan X; Liu F; Peng Y; Zhang H
Curr Hypertens Rep; 2017 Aug; 19(9):72. PubMed ID: 28791529
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations.
Turgut F; Balogun RA; Abdel-Rahman EM
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1330-9. PubMed ID: 20498247
[TBL] [Abstract][Full Text] [Related]
4. Efficacy analysis of the renoprotective effects of aliskiren in hypertensive patients with chronic kidney disease.
Abe M; Suzuki H; Okada K; Maruyama N; Inoshita A; Baba S; Takashima H; Soma M
Heart Vessels; 2013 Jul; 28(4):442-52. PubMed ID: 22618635
[TBL] [Abstract][Full Text] [Related]
5. A model-based approach to investigating the pathophysiological mechanisms of hypertension and response to antihypertensive therapies: extending the Guyton model.
Hallow KM; Lo A; Beh J; Rodrigo M; Ermakov S; Friedman S; de Leon H; Sarkar A; Xiong Y; Sarangapani R; Schmidt H; Webb R; Kondic AG
Am J Physiol Regul Integr Comp Physiol; 2014 May; 306(9):R647-62. PubMed ID: 24500431
[TBL] [Abstract][Full Text] [Related]
6. Reporting of the estimated glomerular filtration rate was associated with increased use of angiotensin-converting enzyme inhibitors and angiotensin-II receptor blockers in CKD.
Jain AK; Cuerden MS; McLeod I; Hemmelgarn B; Akbari A; Tonelli M; Quinn RR; Oliver MJ; Garg AX
Kidney Int; 2012 Jun; 81(12):1248-53. PubMed ID: 22437415
[TBL] [Abstract][Full Text] [Related]
7. The effects of direct renin inhibitor, aliskiren, on arterial hypertension, chronic kidney disease and cardiovascular disease: optimal pharmacotherapy.
Morishita Y; Kusano E
Cardiovasc Hematol Agents Med Chem; 2013 Mar; 11(1):77-82. PubMed ID: 22827288
[TBL] [Abstract][Full Text] [Related]
8. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
9. Hypertension in Chronic Kidney Disease: Novel Insights.
Duni A; Dounousi E; Pavlakou P; Eleftheriadis T; Liakopoulos V
Curr Hypertens Rev; 2020; 16(1):45-54. PubMed ID: 30987570
[TBL] [Abstract][Full Text] [Related]
10. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
Chrysant SG; Chrysant GS
Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
[TBL] [Abstract][Full Text] [Related]
11. Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination.
Cagnoni F; Njwe CA; Zaninelli A; Ricci AR; Daffra D; D'Ospina A; Preti P; Destro M
Vasc Health Risk Manag; 2010 Aug; 6():549-59. PubMed ID: 20730071
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
13. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
Abassi Z; Winaver J; Feuerstein GZ
Biochem Pharmacol; 2009 Oct; 78(8):933-40. PubMed ID: 19477166
[TBL] [Abstract][Full Text] [Related]
14. [Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
Dralova OV; Maksimov ML; Derbentseva EA; Ermolaeva AS; Starodubtsev AK
Eksp Klin Farmakol; 2011; 74(4):14-7. PubMed ID: 21678653
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-(1-7): Translational Avenues in Cardiovascular Control.
Medina D; Arnold AC
Am J Hypertens; 2019 Nov; 32(12):1133-1142. PubMed ID: 31602467
[TBL] [Abstract][Full Text] [Related]
16. Effect of renin-angiotensin-aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis.
Nistor I; De Sutter J; Drechsler C; Goldsmith D; Soler MJ; Tomson C; Wiecek A; Donciu MD; Bolignano D; Van Biesen W; Covic A
Nephrol Dial Transplant; 2018 Jan; 33(1):12-22. PubMed ID: 29106631
[TBL] [Abstract][Full Text] [Related]
17. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
Leon SJ; Tangri N
Can J Cardiol; 2019 Sep; 35(9):1220-1227. PubMed ID: 31472818
[TBL] [Abstract][Full Text] [Related]
18. The Different Therapeutic Choices with ARBs. Which One to Give? When? Why?
Dézsi CA
Am J Cardiovasc Drugs; 2016 Aug; 16(4):255-266. PubMed ID: 26940560
[TBL] [Abstract][Full Text] [Related]
19. Aldosterone sensitivity: an opportunity to explore the pathogenesis of hypertension.
Gray Z; Tu W; Chertow GM; Bhalla V
Am J Physiol Renal Physiol; 2021 Mar; 320(3):F325-F335. PubMed ID: 33491565
[TBL] [Abstract][Full Text] [Related]
20. Is there a future for direct renin inhibitors?
Chaudhary K; Nistala R; Whaley-Connell A
Expert Opin Investig Drugs; 2010 May; 19(5):653-61. PubMed ID: 20380486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
